117 related articles for article (PubMed ID: 338900)
1. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T
J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900
[TBL] [Abstract][Full Text] [Related]
2. Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
Yasumoto M; Yamawaki I; Marunaka T; Hashimoto S
J Med Chem; 1978 Aug; 21(8):738-41. PubMed ID: 357721
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).
Au JL; Sadée W
Cancer Chemother Pharmacol; 1981; 7(1):55-9. PubMed ID: 6804104
[No Abstract] [Full Text] [Related]
4. Synthesis and biological activities of ftorafur metabolites. 3'- and 4'-hydroxyftorafur.
Lin AJ; Benjamin RS; Rao PN; Loo TL
J Med Chem; 1979 Sep; 22(9):1096-100. PubMed ID: 385879
[TBL] [Abstract][Full Text] [Related]
5. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine.
Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H
Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.
El Sayed YM; Sadée W
Biochem Pharmacol; 1982 Sep; 31(18):3006-8. PubMed ID: 6814451
[No Abstract] [Full Text] [Related]
7. Metabolism, antitumor activity, and acute toxicity of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione by oral administration to animals.
Fujii S; Nakamura Y; Takeda S; Morita K; Sato T; Marunaka T; Kawaguchi Y; Unemi N
Gan; 1980 Feb; 71(1):30-44. PubMed ID: 6769737
[TBL] [Abstract][Full Text] [Related]
8. Identification of metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in vitro by rat liver microsomes.
Marunaka T; Minami Y; Umeno Y; Yasuda A; Sato T; Fujii S
Chem Pharm Bull (Tokyo); 1980 Jun; 28(6):1795-80. PubMed ID: 6773678
[No Abstract] [Full Text] [Related]
9. Hydroxylated metabolies of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) in rats and rabbits.
Wu AT; Au JL; Sadée W
Cancer Res; 1978 Jan; 38(1):210-4. PubMed ID: 338145
[TBL] [Abstract][Full Text] [Related]
10. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.
Benvenuto JA; Lu K; Hall SW; Benjamin RS; Loo TL
Cancer Res; 1978 Nov; 38(11 Pt 1):3867-70. PubMed ID: 359130
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P-450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil.
Kawata S; Minami Y; Tarui S; Marunaka T; Okamoto M; Yamano T
Jpn J Pharmacol; 1984 Sep; 36(1):43-9. PubMed ID: 6438379
[TBL] [Abstract][Full Text] [Related]
12. Studies on tetrahydrofuranyl-5-fluorouracils. 2. NMR studies of 1-(tetrahydro-2-furanyl)-, 3-(tetrahydro-2-furanyl)-, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracils.
Yasumoto M; Ueda S; Yamashita J; Hashimoto S
Nucleic Acids Symp Ser; 1979; (6):s85-8. PubMed ID: 121157
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
Au JL; Sadée W
Recent Results Cancer Res; 1981; 76():100-14. PubMed ID: 6785848
[No Abstract] [Full Text] [Related]
14. Metabolism of 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil in mice.
Fujimoto S; Ishigami H; Minami T; Miyazaki M; Itoh K; Kimura K
J Natl Cancer Inst; 1979 Aug; 63(2):465-8. PubMed ID: 379401
[TBL] [Abstract][Full Text] [Related]
15. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.
El Sayed YM; Sadée W
Cancer Res; 1983 Sep; 43(9):4039-44. PubMed ID: 6409396
[TBL] [Abstract][Full Text] [Related]
16. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
17. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
Au JL; Sadée W
Cancer Res; 1980 Aug; 40(8 Pt 1):2814-9. PubMed ID: 6771006
[No Abstract] [Full Text] [Related]
18. Stereoselective metabolism and pharmacokinetics of tegafur.
Damle BD; Narasimhan NI; Kaul S
Biopharm Drug Dispos; 2001 Mar; 22(2):45-52. PubMed ID: 11745907
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence determination of 5-fluorouracil and 1-(tetrahydro-2-furanyl)-5-fluorouracil in blood serum by high-performance liquid chromatography.
Iwamoto M; Yoshida S; Hirose S
J Chromatogr; 1984 Sep; 310(1):151-7. PubMed ID: 6438145
[TBL] [Abstract][Full Text] [Related]
20. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
